Genovis’ project for automatic analysis with the FabRICATOR® enzyme shows proof-of-concept

Genovis’ project to develop automated analysis solutions together with
researchers from Lund Institute of Technology has reached the proof-of-concept
stage, which now must be verified by a number of major industrial players.
“The results are important for Genovis since they clearly show commercial
potential for FabRICATOR® (IdeS) in integrated analysis systems. It is mainly in
quality control in the development and production of biopharmaceuticals that the
system offers major advantages over current methods. We can see that in the long
run this will open up a new market for Genovis’ FabRICATOR® enzyme,” says Sarah
Fredriksson, CEO.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ OMX First North, and Consensus is Certified
Adviser for the Company, t: 46 (0)31-745 50 00